CoChat

Revisiting Plasmodium vivax molecular correction

Taylor, Aimee R, Foo, Yong See, White, Michael T · 2026
PreprintCited by 1

The DOI matches its Crossref record.

Abstract

Background: Reliable inference of Plasmodium vivax recurrence states — relapse, recrudescence and reinfection (the “3Rs”) — improves estimates of antimalarial efficacy. The R package Pv3Rs features a Bayesian model designed for P. vivax molecular correction, i.e., using parasite genetic data to infer recurrence states. The model is an extension of a prototype built to analyse microsatellite data from the Vivax History (VHX) and Best Primaquine Dose (BPD) trials. Methods: We re-analysed data from 212 VHX and BPD trial participants (493 recurrences) using Pv3Rs, comparing results with those from the prototype and with genetic relatedness estimated using Dcifer, a tool for estimating relatedness based on identity-by-descent. Posterior recurrence state probabilities were computed using both uniform and time-to-event priors: artificial but equal prior probabilities facilitate posterior interpretation, while time-to-event priors leverage all available information and enable re-computation of failure rates. Relatedness estimates were used to identify and correct instances of model misspecification. Results: The Pv3Rs model generated posterior probabilities for all recurrences and was able to jointly model data on all episodes per participant for 89% of participants, compared with 73% using the prototype. Recurrence state probabilities were broadly consistent across methods, though the Pv3Rs model elevated reinfection probabilities slightly. Relatedness estimates exposed various outliers consistent with half-sibling parasites and/or genotyping errors. Outlier correction impacted some per-participant failure probabilities, but reinfection-adjusted radical-cure failure rates of high-dose primaquine remained near 3%, in line with previous findings. Conclusion: Re-analysis of VHX and BPD P. vivax genetic data restates earlier reinfection-adjusted efficacy estimates. It demonstrates the increased computational capability and misspecification sensitivity of Pv3Rs, highlighting a need for careful analyses. Using relatedness-based diagnostics alongside model-based inference, we were able to harness the advantages of model-based inference and provide a framework for future P. vivax molecular correction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.64898/2026.06.02.26354709

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. 2014, A high resolution case study of a patient with recurrent plasmodium vivax infections shows that relapses were caused by meiotic siblings, PLoS neglected tropical diseases, 8, e2882, 10.1371/journal.pntd.0002882 · DOI · Paper page
  2. 2013, Malaria burden and artemisinin resistance in the mobile and migrant population on the thai–myanmar border, 1999–2011: an observational study, PLoS medicine, 10, e1001398, 10.1371/journal.pmed.1001398 · DOI · Paper page
  3. 10.1093/cid/ciy319 · DOI · Paper page
  4. 10.1093/cid/ciy735 · DOI
  5. 2025, 14 days of high-dose versus low-dose primaquine treatment in patients with plasmodium vivax infection in cambodia: a randomised, single-centre, open-label efficacy study, The Lancet Infectious Diseases, 25, 884, 10.1016/S1473-3099(25)00033-7 · DOI
  6. 2026, Pv3rs: Plasmodium vivax relapse, recrudescence, and reinfection statistical genetic inference, Bioinformatics, 42, btaf643, 10.1093/bioinformatics/btaf643 · DOI · Paper page
  7. Gerlovina, I. , Berube, S. , Briggs, J. , Murie, K. , Murphy, M. , Wesolowski, A. , and Greenhouse, B. (2025). Classification of outcomes in antimalarial therapeutic efficacy studies with aster. BioRxiv. · doi:10.1101/2025.04.28.651146
  8. 10.1093/genetics/iyac126 · DOI · Paper page
  9. 10.1093/infdis/jir806 · DOI · Paper page
  10. 10.1086/512241 · DOI · Paper page
  11. 2022, Classification of disease recurrence using transition likelihoods with expectation-maximization algorithm, Statistics in medicine, 41, 4697, 10.1002/sim.9534 · doi:10.1002/sim.9534
  12. 2025, Treatment efficacy of dihydroartemisinin–piperaquine for uncomplicated plasmodium falciparum and plasmodium vivax malaria in timika, papua, indonesia, The American Journal of Tropical Medicine and Hygiene, 114, 115
  13. 2025, Microhaplotype deep sequencing assays to capture plasmodium vivax infection lineages, Nature Communications, 16, 7192, 10.1038/s41467-025-62357-x · DOI · Paper page
  14. 2020, Relapse or reinfection: Classification of malaria infection using transition likelihoods, Biometrics, 76, 1351, 10.1111/biom.13226 · doi:10.1111/biom.13226
  15. 2021, Dynamic classification of plasmodium vivax malaria recurrence: An application of classifying unknown cause of failure in competing risks, Journal of data science: JDS, 20, 51
  16. 10.1007/s10739-010-9239-3 · doi:10.1007/s10739-010-9239-3
  17. 2025, Probabilistic classification of late treatment failure in uncomplicated falciparum malaria, Nature Communications, 16, 9880, 10.1038/s41467-025-64830-z · doi:10.1038/s41467-025-64830-z
  18. 2021, Nonparametric binary classification to distinguish closely related versus unrelated plasmodium falciparum parasites, The American Journal of Tropical Medicine and Hygiene, 104, 1830, 10.4269/ajtmh.21-0117 · doi:10.4269/ajtmh.21-0117
  19. 10.1128/AAC.00072-15 · DOI
  20. 10.1128/mBio.01780-18 · DOI
  21. Popovici, J. , Seng, D. , Ko, K. , Orban, A. , Heng, S. , Tat, B. , Feufack-Donfack, L. , Eng, V. , Tebben, K. , Khim, N. , et al. (2026). Frequent and genetically diverse plasmodium vivax relapses contribute to malaria transmission in cambodia. Preprint: Research Square. · DOI · Paper page
  22. Rosado, J. , Han, J. , Obadia, T. , Munro, J. , Traore, Z. , Schoffer, K. , Brewster, J. , Bourke, C. , Vinetz, J. M. , Taylor, A. R. , et al. (2026). Understanding plasmodium vivax recurrent infections using an amplicon deep sequencing assay, identity-by-descent and model-based classification. iScience. · DOI · Paper page
  23. Tadesse, F. G. , Chali, W. , Ejigu, L. A. , Abdo, M. , Kassa, F. A. , Bulto, M. G. , Bezabih, M. K. , Alemayehu, L. , Hundera, N. L. , Bayu, S. L. , et al. (2026). Parasite and gametocyte dynamics and infectivity to mosquitoes during recurrent plasmodium vivax infections; a longitudinal study from ethiopia. Journal of Infection, page 106756. · DOI
  24. Taylor, A. and Foo, Y. S. (2025). Pv3Rs: Estimate the Cause of Recurrent Vivax Malaria using Genetic Data. R package version 1.0.0. · doi:10.32614/cran.package.pv3rs
  25. 2019, Resolving the cause of recurrent plasmodium vivax malaria probabilistically, Nature communications, 10, 5595, 10.1038/s41467-019-13412-x · DOI · Paper page
  26. 2018, Plasmodium vivax and plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses, Malaria journal, 17, 170, 10.1186/s12936-018-2318-1 · DOI

Cited by

See all 1

Metadata

Authors
Taylor, A. R., Foo, Y. S., & White, M. T.
Affiliations
  • Institut Pasteur, Université Paris Cité
  • University of Melbourne
Publisher
openRxiv
Published
2026-06-04
Cited by
1
References
0
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revisiting Plasmodium vivax molecular correction. https://app.cochat.ai/papers/10.64898/2026.06.02.26354709
The paper
Taylor, A. R., Foo, Y. S., & White, M. T. (2026). Revisiting Plasmodium vivax molecular correction. https://doi.org/10.64898/2026.06.02.26354709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.